Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Ashraf Badros, Elizabeth Hyjek, Ning Ma, Alexander Lesokhin, Ahmet Dogan, Aaron P. Rapoport, Mehmet Kocoglu, Emily Lederer, Sunita Philip, Todd Milliron, Cameron Dell, Olga Goloubeva, Zeba Singh

Blood (2017) 130 (10): 1189–1197.

https://doi.org/10.1182/blood-2017-03-775122

Published: 2017

Includes: Supplemental data

Journal Articles

Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

Irene M. Ghobrial, MD, Michael R. Savona, MD, Ravi Vij, David S. Siegel, Ashraf Badros, Jonathan L. Kaufman, MD, Noopur Raje, MD, Andrzej Jakubowiak, MD PhD, Mihaela Obreja, Jesus G. Berdeja, MD

Blood (2016) 128 (22): 2110.

https://doi.org/10.1182/blood.V128.22.2110.2110

Published: 2016

Journal Articles

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Ravi Vij, MBBS, MD, Michael Savona, MD, David S. Siegel, MD PhD, Jonathan L. Kaufman, MD, Ashraf Badros, MD, Irene M. Ghobrial, MD, Agne Paner, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD PhD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Linda L. Neuman, MD MBA, Ju RueyJiuan Lee, PhD, Jesus G. Berdeja, MD

Blood (2014) 124 (21): 34.

https://doi.org/10.1182/blood.V124.21.34.34

Published: 2014

Journal Articles

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

Jesus Berdeja, MD, Sundar Jagannath, MD, Jeffrey Zonder, MD, Ashraf Badros, MD, Jonathan L. Kaufman, MD, Robert Manges, MD, Mark Lynch, PhD, Eric Bleickardt, MD, Prashni Paliwal, PhD, Ravi Vij, MD

Blood (2014) 124 (21): 2119.

https://doi.org/10.1182/blood.V124.21.2119.2119

Published: 2014

Journal Articles

Characteristics and Outcome Of Multiple Myeloma (MM) In African Americans (AA) Receiving Novel Agents and Autologous Stem Cell Transplantation (ASCT)

Vishal Bhatnagar, MD, Yin Wu, MD, Olga Goloubeva, Kathleen Ruehle, RN, Todd Milliron, Saul Yanovich, MD, Aaron P. Rapoport, MD, Ashraf Badros, MD

Blood (2013) 122 (21): 2951.

https://doi.org/10.1182/blood.V122.21.2951.2951

Published: 2013

Journal Articles

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Irene M. Ghobrial, MD, Jonathan L. Kaufman, MD, David S. Siegel, MD, PhD, Ravi Vij, MD, Ashraf Badros, MD, Linda Neuman, MD, Hansen Wong, PhD, Janet Anderl, MS, Michael Savona, MD

Blood (2013) 122 (21): 3184.

https://doi.org/10.1182/blood.V122.21.3184.3184

Published: 2013

Journal Articles

Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)

Ashraf Badros, MD, Sunita Philip, Patricia Lesho, Mariola Sadowska, Dianna Weikel, Timothy Meiller, Rena Lapidus, Lisa Hester, Todd Milliron, Olga Goloubeva

Blood (2013) 122 (21): 3153.

https://doi.org/10.1182/blood.V122.21.3153.3153

Published: 2013

Journal Articles

Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses

Blood (2013) 122 (21): 766.

https://doi.org/10.1182/blood.V122.21.766.766

Published: 2013

Journal Articles

Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib

Blood (2013) 122 (21): 3189.

https://doi.org/10.1182/blood.v122.21.3189.3189

Published: 2013

Journal Articles

Cellular therapy with sequential unmanipulated donor lymphocyte infusions in drug-resistant cytomegalovirus (CMV) encephalitis

Gorgun Akpek, Maria Mikulski, Michael Kleinberg, Ashraf Badros, Saul Yanovich, Aaron P. Rapoport

Blood (2011) 117 (21): 5772–5774.

https://doi.org/10.1182/blood-2011-02-334060

Published: 2011

Journal Articles

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma

Blood (2011) 117 (3): 788–797.

https://doi.org/10.1182/blood-2010-08-299396

Published: 2011

Includes: Supplemental data

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, M.D., Jeffrey Matous, MD, Swaminathan Padmanabhan, MD, Ashraf Badros, MD, Robert Schlossman, MD, Stacey Chuma, RN, Renee Leduc1, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob Soumerai, Diane Warren, Ann Birner, Nikhil Munshi, MD, Steven P. Treon, MD, PhD, Kenneth C. Anderson, MD, Paul Richardson, MD

Blood (2008) 112 (11): 832.

https://doi.org/10.1182/blood.V112.11.832.832

Published: 2008

Journal Articles

Long-Term Follow-Up of Multiple Myeloma (MM) Patients (pts) with Osteonecrosis of the Jaw (ONJ).

Ashraf Badros, T. Evangelos, O. Goloubeva, T. Meiller, E. Kastritis, E. Verrou, K. Zervas, E. Katodritou, E. Streeten, M.R. Baer, M.A. Dimopoulos

Blood (2007) 110 (11): 3519.

https://doi.org/10.1182/blood.V110.11.3519.3519

Published: 2007

Journal Articles

Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts).

Ashraf Badros, S. Philip, R. Niesvizky, O. Goloubeva, C. Harris, J. Zweibel, J. Wright, A. Burger, S. Grant, M.R. Baer, M.J. Egorin

Blood (2007) 110 (11): 1168.

https://doi.org/10.1182/blood.V110.11.1168.1168

Published: 2007

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

Irene M. Ghobrial, Swaminathan Padmanabhan, Ashraf Badros, Marybeth Nelson, Renee Leduc, Xavier Leleu, Diane Warren, Jacob Soumerai, Ann Birner, Robert Schlossman, Nikhil Munshi, Paul Richardson, Steven P. Treon, Kenneth C. Anderson

Blood (2007) 110 (11): 4494.

https://doi.org/10.1182/blood.V110.11.4494.4494

Published: 2007

Journal Articles

High Incidence of BK-Virus-Related Hemorrhagic Cystitis after Busulfan/Fludarabine Myeloablative Conditioning in Allogeneic Stem Cell Transplantation Recipients.

Gorgun Akpek, MD, MHS, Ashraf Badros, MD, Aaron P. Rapoport, MD, Kathleen Ruehle, RN, Kristen Barton, RN, Barry Meisenberg, MD, Saul Yanovich, MD

Blood (2006) 108 (11): 5254.

https://doi.org/10.1182/blood.V108.11.5254.5254

Published: 2006

Journal Articles

Neurotoxicity of Bortezomib Therapy in Multiple Myeloma (MM): A Single Center Experience.

Ashraf Badros, MD, Jay S. Dalal, MD, Olga Goloubeva, PhD, Jenni Thompson, Phrm.D., Kelly Yager, RN, Can Ilyas, MD, Aaron P. Rapoport, MD, Robert G. Fenton, MD, PhD, Gorgun Akpek, MD, Saul Yanovich, MD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 3534.

https://doi.org/10.1182/blood.V108.11.3534.3534

Published: 2006

Journal Articles

Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).

Ashraf Badros, MD, Olga Goloubeva, PhD, Dianna Weikel, DDS, Aaron P. Rapoport, MD, Gorgun Akpek, MD, Saul Yanovich, MD, Timothy Meiller, DDS, PhD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 5026.

https://doi.org/10.1182/blood.V108.11.5026.5026

Published: 2006

Journal Articles

Phase I Trial of Bortezomib (V) in Combination with “DT-PACE”: Toxicity, Stem Cell Collection and Engraftment in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts).

Ashraf Badros, A. Rapoport, O. Goloubeva, K. Ruehle, S. Westphal, S. Hefner, B. Meisenberg

Blood (2005) 106 (11): 2747.

https://doi.org/10.1182/blood.V106.11.2747.2747

Published: 2005

Journal Articles

Bevacizumab therapy for POEMS syndrome

Ashraf Badros, Neil Porter, Ann Zimrin

Blood (2005) 106 (3): 1135.

https://doi.org/10.1182/blood-2005-03-0910

Published: 2005

NARROW

Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma

Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

Characteristics and Outcome Of Multiple Myeloma (MM) In African Americans (AA) Receiving Novel Agents and Autologous Stem Cell Transplantation (ASCT)

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)

Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses

Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib

Cellular therapy with sequential unmanipulated donor lymphocyte infusions in drug-resistant cytomegalovirus (CMV) encephalitis

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Long-Term Follow-Up of Multiple Myeloma (MM) Patients (pts) with Osteonecrosis of the Jaw (ONJ).

Phase I Trial of Suberoylanilide Hydroxamic Acid (SAHA) + Bortezomib (Bort) in Relapsed Multiple Myeloma (MM) Patients (pts).

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.

High Incidence of BK-Virus-Related Hemorrhagic Cystitis after Busulfan/Fludarabine Myeloablative Conditioning in Allogeneic Stem Cell Transplantation Recipients.

Neurotoxicity of Bortezomib Therapy in Multiple Myeloma (MM): A Single Center Experience.

Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).

Phase I Trial of Bortezomib (V) in Combination with “DT-PACE”: Toxicity, Stem Cell Collection and Engraftment in Newly Diagnosed Multiple Myeloma (MM) Patients (Pts).

Bevacizumab therapy for POEMS syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only